Company Overview - Beijing Baipusi Biotechnology Co., Ltd. is located in Daxing District, Beijing, and was established on July 22, 2010. The company went public on October 18, 2021. Its main business involves providing key biological reagent products and technical services, with revenue composition as follows: 82.27% from recombinant proteins, 12.88% from antibodies and other reagents, 3.04% from technical services, and 1.80% from other sources [1]. Stock Performance - On October 13, Baipusi's stock fell by 5.21%, closing at 58.20 CNY per share, with a trading volume of 138 million CNY and a turnover rate of 1.82%. The total market capitalization is 9.769 billion CNY [1]. Fund Holdings - Silver Hua Fund has a significant position in Baipusi, with its Silver Hua Healthcare Mixed A Fund (018364) holding 40,500 shares, accounting for 5.42% of the fund's net value, making it the third-largest holding. The estimated floating loss today is approximately 129,600 CNY [2]. Fund Manager Performance - The fund manager Zhang Ping has been in position for 6 years and 344 days, managing assets totaling 20.578 billion CNY, with the best fund return during her tenure being 205.15% and the worst being -35.16%. Co-manager Wang Lu has been in position for 2 years and 284 days, managing 2.301 billion CNY, with a best return of 18.53% and a worst return of -2.8% [3].

Core Viewpoint - Beijing Baipusi Biotechnology Co., Ltd. has shown a significant stock price increase of 5.07%, reaching 62.58 CNY per share, with a total market capitalization of 10.504 billion CNY as of October 9 [1] Company Overview - Baipusi was established on July 22, 2010, and went public on October 18, 2021. The company is located in Beijing Economic and Technological Development Zone [1] - The main business involves providing key biological reagent products and technical services, with revenue composition as follows: 82.27% from recombinant proteins, 12.88% from antibodies and other reagents, 3.04% from technical services, and 1.80% from other sources [1] Fund Holdings - Tianhong Fund has a significant holding in Baipusi, with Tianhong Healthcare A (001558) owning 414,200 shares, representing 5.9% of the fund's net value, making it the seventh-largest holding [2] - The fund has realized a floating profit of approximately 1.251 million CNY from this investment [2] Fund Performance - Tianhong Healthcare A was established on June 30, 2015, with a current size of 251 million CNY. The fund has achieved a year-to-date return of 44.49%, ranking 1774 out of 8238 in its category [2] - Over the past year, the fund has returned 34.83%, ranking 2489 out of 8082, and since inception, it has delivered a return of 81.87% [2]

证券代码：301080 证券简称：百普赛斯 公告编号：2025-065 北京百普赛斯生物科技股份有限公司 关于实际控制人之一致行动人减持股份触及 1%整数倍的公告 股份比例由 42.27%减少至 41.62%（占剔除回购专用账户股份后公司总股本的比 例由 42.44%减少至 41.78%），合计持有权益变动触及 1%的整数倍。现将有关情 况公告如下： | 1、基本情况 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 息 披 | | | | | | 务 | | | | | | | 信 露 义 | | | | | | | | | | | | | | | 陈宜顶 | | | 1 | ...

Market Overview - The biopharmaceutical sector increased by 0.78% on September 29, with Norseland leading the gains [1] - The Shanghai Composite Index closed at 3862.53, up 0.9%, while the Shenzhen Component Index closed at 13479.43, up 2.05% [1] Top Gainers in Biopharmaceutical Sector - Norseland (Code: 430047) closed at 24.80, up 6.57% with a trading volume of 68,400 shares and a transaction value of 169 million yuan [1] - Liaoning Chengda (Code: 600739) closed at 12.54, up 4.85% with a trading volume of 311,400 shares and a transaction value of 384 million yuan [1] - Rongchang Biotech (Code: 688331) closed at 110.00, up 4.76% with a trading volume of 83,500 shares and a transaction value of 900 million yuan [1] Top Losers in Biopharmaceutical Sector - Kanghua Biotech (Code: 300841) closed at 75.47, down 2.34% with a trading volume of 40,800 shares and a transaction value of 307 million yuan [2] - Baipusais (Code: 301080) closed at 58.51, down 2.32% with a trading volume of 20,000 shares and a transaction value of 117 million yuan [2] - Rili Pharmaceutical (Code: 603087) closed at 76.37, down 2.18% with a trading volume of 120,740 shares and a transaction value of 1.573 billion yuan [2] Capital Flow Analysis - The biopharmaceutical sector experienced a net outflow of 154 million yuan from institutional investors, while retail investors saw a net inflow of 1.47 billion yuan [2] - The sector's overall capital flow indicates a mixed sentiment, with institutional investors withdrawing funds while retail investors are actively buying [2][3] Individual Stock Capital Flow - Liaoning Chengda saw a net outflow of 52.59 million yuan from institutional investors, while retail investors had a net outflow of 40.07 million yuan [3] - Kanghua Biotech had a net inflow of 26.12 million yuan from institutional investors, but a net outflow of 47.70 million yuan from retail investors [3] - Three Life National Health (Code: 688336) had a net inflow of 23.37 million yuan from institutional investors, with retail investors also experiencing a net outflow [3]

Core Viewpoint - The announcement details the share reduction plans of the actual controller and associated parties of Baipusais, indicating a significant decrease in their shareholding percentage, which has implications for investor sentiment and market perception [1][2]. Share Reduction Plans - The actual controller Chen Yiding's associated party Miao Jingyun plans to reduce holdings by up to 400,000 shares from September 5, 2025, to December 4, 2025, representing 0.24% of the total share capital [1]. - The associated parties Anyi Baipusais and Anyi Baijiale plan to reduce holdings by up to 4,600,000 shares during the same period, accounting for 2.74% of the total share capital [1]. Recent Share Reduction Activity - Between September 11, 2025, and September 25, 2025, Miao Jingyun reduced holdings by 42,300 shares, while Anyi Baipusais and Anyi Baijiale reduced holdings by 1,919,045 shares and 257,810 shares, respectively, totaling 2,219,155 shares, which is 1.32% of the total share capital [2]. - The total cash generated from these reductions is approximately 132 million yuan, based on a share price of 59.48 yuan [2]. Changes in Shareholding Structure - Following the reductions, the combined shareholding of the actual controller and associated parties decreased from 43.59% to 42.27% of the total share capital [2]. - The shareholding percentage, excluding repurchased shares, decreased from 43.77% to 42.44% [2]. Historical Context - Baipusais was listed on the Shenzhen Stock Exchange on October 18, 2021, with an initial public offering of 20 million shares at a price of 112.50 yuan per share, raising a total of 2.25 billion yuan [3]. - The company had originally planned to raise 937 million yuan for various projects, including R&D and marketing upgrades [3]. Financial Information - The total issuance costs for the IPO amounted to 156 million yuan, with underwriting fees of 135 million yuan [4]. - The company announced a stock split and dividend distribution in 2023 and 2025, indicating ongoing shareholder engagement [4].

北京百普赛斯生物科技股份有限公司 关于实际控制人之一致行动人减持股份触及 1%整数倍的公告 公司实际控制人之一致行动人苗景赟先生、安义百普赛斯企业管理 咨询合伙企业（有限合伙）、安义百普嘉乐企业管理咨询合伙企业（有 限合伙）保证向本公司提供的信息内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信 息一致。 证券代码：301080 证券简称：百普赛斯 公告编号：2025-064 北京百普赛斯生物科技股份有限公司（以下简称"公司"或"本公司"）于 2025 年 8 月 14 日在巨潮资讯网（http://www.cninfo.com.cn）上披露了《关于实际控制 人之一致行动人及高级管理人员减持股份的预披露公告》（公告编号：2025-048）。 公司实际控制人陈宜顶先生的一致行动人苗景赟先生计划自 2025 年 9 月 5 日至 2025 年 12 月 4 日以集中竞价或大宗交易方式减持所持有的公司股份合计不超过 400,000 股（占公司总股本的 0.24%，占公司剔除回购专用账户中股份数量后股份 总数的 0.24%）。公司实际控制人陈宜顶先 ...

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 9月26日，百普赛斯收跌3.64%，收盘价为59.90元，发生2笔大宗交易，合计成交量110万股，成交金额 6015.9万元。 第1笔成交价格为54.69元，成交80.00万股，成交金额4,375.20万元，溢价率为-8.70%，买方营业部为平 安证券股份有限公司湖北分公司，卖方营业部为中银国际证券股份有限公司北京经济技术开发区证券营 业部。 第2笔成交价格为54.69元，成交30.00万股，成交金额1,640.70万元，溢价率为-8.70%，买方营业部为平 安证券股份有限公司湖北分公司，卖方营业部为中银国际证券股份有限公司北京经济技术开发区证券营 业部。 进一步统计，近3个月内该股累计发生22笔大宗交易，合计成交金额为1.34亿元。该股近5个交易日累计 上涨1.91%，主力资金合计净流出1497.73万元。 责任编辑：小浪快报 ...

百普赛斯9月26日大宗交易平台共发生2笔成交，合计成交量110.00万股，成交金额6015.90万元。成交价 格均为54.69元，相对今日收盘价折价8.70%。 进一步统计，近3个月内该股累计发生22笔大宗交易，合计成交金额为1.34亿元。 证券时报·数据宝统计显示，百普赛斯今日收盘价为59.90元，下跌3.64%，日换手率为2.13%，成交额为 1.63亿元，全天主力资金净流入442.36万元，近5日该股累计上涨1.91%，近5日资金合计净流出1451.02 万元。 两融数据显示，该股最新融资余额为1.13亿元，近5日增加992.24万元，增幅为9.67%。（数据宝） 9月26日百普赛斯大宗交易一览 | 成交量 | 成交金额 | 成交价 | 相对当日收盘 | | | | --- | --- | --- | --- | --- | --- | | （万 | （万元） | 格 | 折溢价（%） | 买方营业部 | 卖方营业部 | | 股） | | （元） | | | | | 80.00 | 4375.20 | 54.69 | -8.70 | 平安证券股份有限 | 中银国际证券股份有限公司北京 | | | | | ...

Core Viewpoint - The company, Beijing Baipusi Biotechnology Co., Ltd., has shown significant growth in revenue and net profit, indicating a strong performance in the biotechnology sector. Group 1: Financial Performance - As of June 30, 2025, the company achieved a revenue of 387 million yuan, representing a year-on-year growth of 29.38% [2] - The net profit attributable to shareholders reached 83.80 million yuan, with a year-on-year increase of 47.81% [2] Group 2: Shareholder and Market Activity - On September 25, 2023, the company's stock price increased by 3.43%, with a trading volume of 271 million yuan [1] - The number of shareholders increased to 11,700, up by 10.85% compared to the previous period [2] - The average number of circulating shares per shareholder decreased by 9.79% to 7,711 shares [2] Group 3: Financing and Margin Trading - On September 25, 2023, the company had a net financing purchase of 10.03 million yuan, with a total financing balance of 113 million yuan, accounting for 1.08% of the market capitalization [1] - The company’s margin trading balance is at a high level, exceeding the 90th percentile over the past year [1] Group 4: Dividend Distribution - The company has distributed a total of 432 million yuan in dividends since its A-share listing, with 312 million yuan distributed in the last three years [3] Group 5: Institutional Holdings - As of June 30, 2025, Hong Kong Central Clearing Limited is the third-largest circulating shareholder, holding 5.9863 million shares, an increase of 3.7571 million shares from the previous period [3] - The sixth-largest circulating shareholder, China Europe Medical Health Mixed A, holds 3.2163 million shares, an increase of 0.5904 million shares [3]

Market Overview - The biopharmaceutical sector experienced a decline of 0.21% on September 25, with Nossland leading the drop [1] - The Shanghai Composite Index closed at 3853.3, down 0.01%, while the Shenzhen Component Index closed at 13445.9, up 0.67% [1] Stock Performance - Notable gainers in the biopharmaceutical sector included: - Aopu Mai (688293) with a closing price of 62.85, up 7.42% and a trading volume of 30,600 [1] - Rongchang Biotech (688331) closed at 108.50, up 3.43% with a trading volume of 89,200 [1] - Baipusais (301080) closed at 62.16, up 3.43% with a trading volume of 43,500 [1] - Major decliners included: - Nossland (430047) closed at 22.99, down 3.69% with a trading volume of 57,000 [2] - Wufan Biotech (301393) closed at 53.12, down 3.42% with a trading volume of 24,600 [2] - Kexing Pharmaceutical (688136) closed at 38.75, down 3.34% with a trading volume of 53,500 [2] Capital Flow - The biopharmaceutical sector saw a net outflow of 207 million yuan from institutional investors, while retail investors contributed a net inflow of 45.07 million yuan [2] - Notable capital flows included: - Rongchang Biotech (688331) with a net inflow of 1.021 billion yuan from institutional investors [3] - Junshi Biosciences (688180) with a net inflow of 35.36 million yuan from institutional investors [3] - Aopu Mai (688293) with a net inflow of 9.41 million yuan from institutional investors [3]